The appointment of Sebastián Almeida to TAAV brings over 20 years of technical operations, biomanufacturing experience, and significant experience in biopharmaceutical product management, development, and manufacturing. TAAV, a wholly owned subsidiary of AskBio and Bayer AG, is a cGMP manufacturer of enzymatic DNA material used for adeno-associated virus (AAV) gene therapies. Headquartered in San Sebastian, Spain, the company also has its manufacturing facilities and lab located in the same region.
Throughout his career, Mr. Almeida has specialized in bioprocess development, technology transfer, and manufacturing. He holds a degree in Molecular Biology from CAECE University in Argentina, as well as a Postgraduate Diploma in Quality Management from ITBA in Argentina. His vast international experience has enabled him to effectively manage and collaborate with multidisciplinary teams across South America, Europe, Asia, and North America.
Mr. Almeida will lead the Manufacturing Department at TAAV. His focus will be to enhance TAAV’s manufacturing capabilities to the next level, particularly its innovative neDNA™ technology. The neDNA™ technology aims to provide clients with solutions to overcome challenges related to current industry solutions. Unlike the common plasmid DNA manufacturing process, neDNA™ is produced without the use of fermenters and bacteria, which results in an enzymatic DNA product with an improved safety profile for the manufacture of recombinant adeno-associated virus (rAAV) gene therapy vectors.
TAAV, alongside Sebastián, will be hosting a webinar, here with Phacilitate, discussing overcoming quality and regulatory challenges for the next era of rAAV. Don’t miss it, register now.
Lee Buckler, SVP Advanced Therapies, Blood Centers of America, Advanced Therapies Network, reflects on two decades of working within the advanced therapies industry as Phacilitate celebrates 20 years of operating in the field.